Literature DB >> 29516208

Time-dependent change in relapse sites of renal cell carcinoma after curative surgery.

Go Noguchi1,2, Noboru Nakaigawa3, Masataka Taguri4, Sohgo Tsutsumi2, Yoko Saito5, Sachi Fukui6, Masato Yasui2, Takashi Tokita7, Taku Mitome8, Tomoyuki Tatenuma9, Shinnosuke Kuroda1, Koichi Abe8, Daiki Ueno6, Kazuhiro Namura8, Susumu Umemoto2, Akitoshi Takizawa6, Junichi Ohta10, Teiichiro Ueki5, Takeshi Watanabe9, Kazuki Kobayashi8, Keiichi Kondo1, Takeshi Kishida2, Hitomi Kanno7, Kazuo Kitami11, Takeharu Yamanaka4, Masahiro Yao1.   

Abstract

We investigated time-dependent changes in the relapse features of renal cell carcinoma (RCC) after curative surgery. Between 1985 and 2015, 1398 patients with RCC (1226 clear cell RCC, 89 papillary RCC, and 53 chromophobe RCC) underwent curative surgery at Yokohama City University Hospital and its affiliated hospitals. We retrospectively reviewed the clinicopathologic factors of patients with relapse after surgery. Median follow-up was 56.3 months. Recurrence occurred in 245 patients (217 clear cell RCC, 12 papillary RCC, and 3 chromophobe RCC). Papillary RCC and chromophobe RCC had no recurrence beyond 5 years after surgery, but 20 cases of clear cell carcinoma had recurrence beyond 10 years after surgery. The typical recurrence sites of clear cell RCC were lung (46.6%), bone (17.9%), liver (7.6%), and lymph nodes (6.5%). The proportion of recurrences at these typical sites was 83.9% for recurrences within 5 years, 76.3% between 5 and 10 years, and 40.0% beyond 10 years. In contrast, the proportion of retroperitoneal organ recurrence, including contralateral kidney, pancreas, and adrenal glands, increased with increasing time after surgery. Interestingly, the hazard ratio of typical site relapse decreased whereas that of retroperitoneal organ relapse increased in a time-dependent manner. In summary, clear cell RCC showed potential to relapse beyond 10 years after surgery. Recurrence at typical sites decreased whereas retroperitoneal organ recurrence increased in a time-dependent manner. Clinicians should check for recurrence at various sites beyond 10 years, especially in clear cell RCC.

Entities:  

Keywords:  Late recurrence; Metastasis; Relapse site; Renal cell carcinoma; Surveillance

Mesh:

Year:  2018        PMID: 29516208     DOI: 10.1007/s10585-018-9883-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  20 in total

Review 1.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

2.  Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer.

Authors:  Noriomi Miyao; Seiji Naito; Seiichiro Ozono; Nobuo Shinohara; Naoya Masumori; Tatsuo Igarashi; Masahiro Nakao; Tomoyasu Tsushima; Yutaka Senga; Shigeo Horie; Hiro-omi Kanayama; Noriaki Tokuda; Mikio Kobayashi
Journal:  Urology       Date:  2010-10-23       Impact factor: 2.649

3.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.

Authors:  John S Lam; Oleg Shvarts; John T Leppert; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2005-08       Impact factor: 7.450

4.  Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients.

Authors:  Sei Naito; Hidefumi Kinoshita; Tsunenori Kondo; Nobuo Shinohara; Takashi Kasahara; Kazutaka Saito; Tatsuya Takayama; Naoya Masumori; Wataru Takahashi; Masayuki Takahashi; Toshiro Terachi; Seiichiro Ozono; Seiji Naito; Yoshihiko Tomita
Journal:  Urology       Date:  2013-10       Impact factor: 2.649

5.  The role of metastasectomy in metastatic renal cell carcinoma.

Authors:  Michael Staehler
Journal:  Nat Rev Urol       Date:  2011-04       Impact factor: 14.432

6.  Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).

Authors:  Sabine Brookman-May; Matthias May; Shahrokh F Shariat; Evanguelos Xylinas; Christian Stief; Richard Zigeuner; Thomas Chromecki; Maximilian Burger; Wolf F Wieland; Luca Cindolo; Luigi Schips; Ottavio De Cobelli; Bernardo Rocco; Cosimo De Nunzio; Bogdan Feciche; Michael Truss; Christian Gilfrich; Sascha Pahernik; Markus Hohenfellner; Stefan Zastrow; Manfred P Wirth; Giacomo Novara; Marco Carini; Andrea Minervini; Claudio Simeone; Alessandro Antonelli; Vincenzo Mirone; Nicola Longo; Alchiede Simonato; Giorgio Carmignani; Vincenzo Ficarra
Journal:  Eur Urol       Date:  2012-06-22       Impact factor: 20.096

7.  Differences in organ system of distant metastasis by renal cell carcinoma subtype.

Authors:  Nathan E Hoffmann; Michael D Gillett; John C Cheville; Christine M Lohse; Bradley C Leibovich; Michael L Blute
Journal:  J Urol       Date:  2008-02       Impact factor: 7.450

8.  Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancer.

Authors:  Reiki Nishimura; Tomofumi Osako; Yasuyuki Nishiyama; Rumiko Tashima; Masahiro Nakano; Mamiko Fujisue; Yasuo Toyozumi; Nobuyuki Arima
Journal:  Oncology       Date:  2013-07-17       Impact factor: 2.935

Review 9.  Recent progress in the management of advanced renal cell carcinoma.

Authors:  Jorge A Garcia; Brian I Rini
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

10.  Features, risk factors and clinical outcome of "very late" recurrences after surgery for localized renal carcinoma: A retrospective evaluation of a cohort with a minimum of 10 years of follow up.

Authors:  Alessandro Antonelli; Maria Furlan; Mario Sodano; Luca Cindolo; Sandra Belotti; Regina Tardanico; Alberto Cozzoli; Tiziano Zanotelli; Claudio Simeone
Journal:  Int J Urol       Date:  2015-11-14       Impact factor: 3.369

View more
  4 in total

1.  Lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating BMPR1A lysosomal degradation.

Authors:  Bo Jiang; Xiaozhi Zhao; Wei Chen; Wenli Diao; Meng Ding; Haixiang Qin; Binghua Li; Wenmin Cao; Wei Chen; Yao Fu; Kuiqiang He; Jie Gao; Mengxia Chen; Tingsheng Lin; Yongming Deng; Chao Yan; Hongqian Guo
Journal:  Nat Commun       Date:  2022-07-16       Impact factor: 17.694

2.  MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.

Authors:  Ryoma Kurahashi; Tsuyoshi Kadomatsu; Masaya Baba; Chiaki Hara; Hitoshi Itoh; Keishi Miyata; Motoyoshi Endo; Jun Morinaga; Kazutoyo Terada; Kimi Araki; Masatoshi Eto; Laura S Schmidt; Tomomi Kamba; W Marston Linehan; Yuichi Oike
Journal:  Cancer Sci       Date:  2019-05-24       Impact factor: 6.716

3.  Isolated late intradural cauda equina metastasis of renal cell carcinoma.

Authors:  Sundus Ali; Adnan Qasim; Rahmatullah Salah; Muhammad Rizwan Sarwar; Muhammad Usman; Shahzad Shams
Journal:  Surg Neurol Int       Date:  2021-09-30

4.  A case report of the pancreatic and periampullary metastases of renal cell carcinoma, 17 years after surgery.

Authors:  Ruiling Lu; Ying Ying; Zhenhua Zhu; Hongping Wan; Guohua Li; Xu Shu; Wangdi Liao
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.